LAUPHEIM, Germany and MILFORD, Mass., Jan. 22, 2026 — Rentschler Biopharma SE, a premier global contract development and manufacturing organization (CDMO) specializing in biopharmaceuticals, has announced the return of Detra Glinatsis to the company as Head of Business Development U.S. In this newly established position, Ms. Glinatsis will oversee all business development initiatives for the U.S. market. She will report to Dr. Patrick Meyer, Global Head of Business Development, and will be based at the company’s facility in Milford, MA.
Dr. Patrick Meyer, Global Head of Business Development at Rentschler Biopharma, stated: “We are delighted to welcome Detra back to Rentschler Biopharma for this significant role. Her career trajectory clearly demonstrates her expertise, a strong focus on clients, and a proven ability to cultivate enduring and valuable partnerships. The United States is a vital component of our commercial strategy, and our presence in Milford, MA allows us to bring Rentschler Biopharma’s innovative approach and development capabilities directly to our clients. In the past two years, we have successfully transitioned one post-PPQ* commercial program to the site, are progressing three additional programs towards PPQ, and commenced manufacturing for six new products in 2025 – clear indicators of the momentum Detra will now help to accelerate. Expanding our U.S. operations is crucial for the next phase of our corporate growth strategy, and Detra, with her dedication to excellence and surpassing client expectations, is the ideal leader for our U.S. business development efforts.”
Detra Glinatsis brings more than two decades of experience in sales and business development within the pharmaceutical, biotech, and contract manufacturing sectors. She returns to Rentschler Biopharma from Northway Biotech, where she held the position of Vice President, Business Development. Previously, she held progressively responsible roles at AGC Biologics, Sartorius, Gallus BioPharmaceuticals, and Avecia Biologics, as well as at Rentschler Biopharma, where she previously served as Senior Director, Business Development. Ms. Glinatsis earned a B.S. in biology from the University of Akron.
Detra Glinatsis, Head of Business Development U.S., commented: “I am very pleased to return to Rentschler Biopharma as the company continues to expand its U.S. presence. Working alongside the team, I am eager to build upon the success the company has achieved with the Milford site expansion and to further strengthen the Rentschler Biopharma brand in the U.S. The company is renowned for its long-standing commitment to top quality and reliability, and I am excited to collaborate with such a skilled team that possesses a highly respected track record.”
_________
* PPQ = Process Performance Qualification
About Rentschler Biopharma SE
Rentschler Biopharma is a leading contract development and manufacturing organization (CDMO) dedicated exclusively to client projects. The company provides process development and manufacturing services for biopharmaceuticals, along with related consulting, project management, and regulatory support. Rentschler Biopharma’s high standards of quality are evidenced by its extensive experience and its role as a trusted solution partner for its clients. A robust quality management system, a well-established operational excellence philosophy, and advanced technologies ensure product quality and productivity at every stage of development and manufacturing. Rentschler Biopharma is a family-owned company with approximately 1,400 employees, headquartered in Laupheim, Germany, and with operations in Milford, MA, USA. In 2024, the company became a signatory to the United Nations Global Compact, underscoring Rentschler Biopharma’s commitment to sustainability. For more information about the company, please visit . Follow Rentschler Biopharma on .
Contact:
Rentschler Biopharma SE
Dr. Latika Bhonsle-Deeng
Global Head of Communications
Phone: +49-7392-701-467
Media inquiries:
| MC Services AG Eva Bauer Phone: +49-89-210228-0 |
U.S. Laurie Doyle Phone: +1-339-832-0752 |
